New Zealand - English - Medsafe (Medicines Safety Authority)

amgen new zealand limited - denosumab 60 mg/ml;   - solution for injection - 60 mg/ml - active: denosumab 60 mg/ml   excipient: acetic acid polysorbate 20 sodium hydroxide sorbitol water for injection - the treatment of osteoporosis in postmenopausal women. prolia® significantly reduces the risk of vertebral, non-vertebral and hip fractures. treatment to increase bone mass in men with osteoporosis at increased risk of fracture.

New Zealand - English - Medsafe (Medicines Safety Authority)

amgen new zealand limited - denosumab 120mg;   - solution for injection - 70 mg/ml - active: denosumab 120mg   excipient: glacial acetic acid polysorbate 20 sodium hydroxide sorbitol water for injection - indicated for the prevention of skeletal related events in patients with bone metastases from solid tumours.

New Zealand - English - Medsafe (Medicines Safety Authority)

amgen new zealand limited - cinacalcet hydrochloride 33mg (r - enantiomer, anhydrate, equivalent to 30mg cinacalcet as the free base) - film coated tablet - 30 mg - active: cinacalcet hydrochloride 33mg (r - enantiomer, anhydrate, equivalent to 30mg cinacalcet as the free base) excipient: carnauba wax colloidal silicon dioxide crospovidone magnesium stearate microcrystalline cellulose opadry clear ys-1-19025-a opadry green povidone starch - sensipar may be used to treat the biochemical manifestations of secondary hyperparathyroidism in adult patients with end stage renal disease, receiving dialysis. sensipar should be used as adjunctive therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

amgen new zealand limited - cinacalcet hydrochloride 66mg (r - enantiomer, anhydrate, equivalent to 60mg cinacalcet as the free base) - film coated tablet - 60 mg - active: cinacalcet hydrochloride 66mg (r - enantiomer, anhydrate, equivalent to 60mg cinacalcet as the free base) excipient: carnauba wax colloidal silicon dioxide crospovidone magnesium stearate microcrystalline cellulose opadry clear ys-1-19025-a opadry green povidone starch - sensipar may be used to treat the biochemical manifestations of secondary hyperparathyroidism in adult patients with end stage renal disease, receiving dialysis. sensipar should be used as adjunctive therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

amgen new zealand limited - cinacalcet hydrochloride 99mg (r - enantiomer, anhydrate, equivalent to 90mg cinacalcet as the free base) - film coated tablet - 90 mg - active: cinacalcet hydrochloride 99mg (r - enantiomer, anhydrate, equivalent to 90mg cinacalcet as the free base) excipient: carnauba wax colloidal silicon dioxide crospovidone magnesium stearate microcrystalline cellulose opadry clear ys-1-19025-a opadry green povidone starch - sensipar may be used to treat the biochemical manifestations of secondary hyperparathyroidism in adult patients with end stage renal disease, receiving dialysis. sensipar should be used as adjunctive therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

amgen new zealand limited - carfilzomib 30mg;  ;   - powder for infusion - 30 mg - active: carfilzomib 30mg     excipient: citric acid sodium hydroxide sulfobutyl betadex sodium - kyprolis in combination with either lenalidomide and dexamethasone, or dexamethasone alone, is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

amgen new zealand limited - carfilzomib 60mg;  ;   - powder for infusion - 60 mg - active: carfilzomib 60mg     excipient: citric acid sodium hydroxide sulfobutyl betadex sodium - kyprolis in combination with either lenalidomide and dexamethasone, or dexamethasone alone, is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

amgen new zealand limited - adalimumab 50 mg/ml;   - solution for injection - 20 mg/0.4ml - active: adalimumab 50 mg/ml   excipient: glacial acetic acid polysorbate 80 sodium hydroxide sucrose water for injection - rheumatoid arthritis amgevita is indicated for reducing signs and symptoms, as well as inhibiting the progression of structural damage in adult patients with moderate to severely active rheumatoid arthritis. this includes the treatment of patients with recently diagnosed moderate to severely active disease who have not received methotrexate. amgevita can be used alone or in combination with methotrexate.

New Zealand - English - Medsafe (Medicines Safety Authority)

amgen new zealand limited - adalimumab 50 mg/ml;   - solution for injection - 40 mg/0.8ml - active: adalimumab 50 mg/ml   excipient: glacial acetic acid polysorbate 80 sodium hydroxide sucrose water for injection - rheumatoid arthritis amgevita is indicated for reducing signs and symptoms, as well as inhibiting the progression of structural damage in adult patients with moderate to severely active rheumatoid arthritis. this includes the treatment of patients with recently diagnosed moderate to severely active disease who have not received methotrexate. amgevita can be used alone or in combination with methotrexate.

New Zealand - English - Medsafe (Medicines Safety Authority)

amgen new zealand limited - adalimumab 50 mg/ml;   - solution for injection - 40 mg/0.8ml - active: adalimumab 50 mg/ml   excipient: glacial acetic acid polysorbate 80 sodium hydroxide sucrose water for injection - rheumatoid arthritis amgevita is indicated for reducing signs and symptoms, as well as inhibiting the progression of structural damage in adult patients with moderate to severely active rheumatoid arthritis. this includes the treatment of patients with recently diagnosed moderate to severely active disease who have not received methotrexate. amgevita can be used alone or in combination with methotrexate.